Recommendation of the President – Lokelma (sodium zirconium cyclosilicate)
On 31 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 159/2024 on the appraisal Lokelma (sodium zirconium cyclosilicate) in prescription pharmacy for the indication: treatment of hyperkalemia in adult patients in the course of chronic kidney disease grade 3b-5, in patients taking drugs from the group of inhibitors of the renin-angiotensin-aldosterone system (ACE inhibitors and inhibitors of the receptor for angiotensin)